Issues in Healthcare and Pharmacology for Vulnerable Populations
Special issue call for papers from International Journal of Pharmaceutical and Healthcare Marketing
Vulnerability to health care quality problems can be due to a combination of underlying reasons, including those pertaining to financial circumstances or place of residence; health, age, or functional or developmental status; or ability to communicate effectively. Other personal characteristics, such as race, ethnicity, and sex can also be associated with differential experiences in obtaining quality health care. Furthermore, characteristics of the evolving health system can interact with personal characteristics to contribute to vulnerability. Understanding the underlying sources of vulnerability is critical, not only because of the need to influence the development of targeted quality improvement efforts, but also because addressing the problems vulnerable groups encounter requires coordinated efforts throughout the health system. In particular, populations vulnerable to health care quality problems need to be accounted for in the design of effective systems for health care delivery, the choice of appropriate health care quality measures, and the adaptation of effective communication and education strategies.
Vulnerable populations require special attention in the design of health care quality measurement strategies for three distinct reasons. First, a focus on the quality of care experienced by vulnerable populations could provide new insight into health system problems or identification of problems that otherwise could go undetected. Second, some vulnerable groups are underserved or lack service all together, thus it is important to understand the barriers they face. The same factors that contribute to their vulnerability can also affect their ability to safeguard their own needs and interests adequately. Third, for a variety of technical and other reasons, poor communications with vulnerable populations exasperates the problems.
All papers should look at these vulnerability issues and have a strong marketing or management perspective and will need to make a distinct contribution to the emerging research on the pharmaceutical and healthcare sectors. Empirical research, conceptual papers, literature reviews, case studies, quantitative models, qualitative studies, and pedagogical innovations (syllabus development) are all welcome. Papers can adopt a historical perspective, a current perspective or a future perspective.
Below is a list of topics that are consistent with the scope of the special issue, but other relevant topics are also welcome:
• Ageing population issues
• Healthcare issues in rural areas
• Pharmacology issues in rural areas
• New business models for addressing issues of vulnerable populations
• Disruptive innovations as solutions for vulnerable populations
• Public policy initiatives
• Patient education
• Marketing and communication strategies specific to vulnerable populations
Submission Procedures for Prospective Authors
We welcome submissions that clearly focus on the needs of industry and provide robust theoretical foundations integrated with empirical studies. These include but are not limited to new frameworks using multidisciplinary and interdisciplinary explanations. We are particularly interested in research that analyses issues in healthcare and pharmacology that are focused on vulnerable populations. Submitted papers should not have been previously published nor be currently under consideration for publication elsewhere. Full papers must be submitted by December 1, 2016 through ScholarOne Manuscripts, the online submission and peer review system at: https://mc.manuscriptcentral.com/ijphm. Please select the correct issue to submit to: "Issues in Healthcare and Pharmacology for Vulnerable Populations". For more details and manuscript guidelines, please visit the official website at:
Each paper submitted to this special issue is subject to the following review procedures:
1. It will be reviewed by the guest editors for general suitability for this special issue.
2. If found suitable, reviewers will be selected for a double-blind review process.
3. Based on the reviewers' recommendation, the guest editors and the Editor-in-Chief will decide whether the particular submission should be accepted as it is, revised and re-submitted, or rejected.
4. The complete review cycle will be 16 weeks or less.
FULL Paper Submissions: December 1, 2016
Revisions and Decisions: January – February 2017
Publication: June 2017
J. Michael Weber
Professor of Marketing and Associate Dean
Stetson School of Business and Economics
James L. Oakley
Associate Professor of Marketing
College of Business
Editor in Chief
Professor and Dean
College of Business
Clayton State University